{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:45:18Z","timestamp":1777729518657,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Dysregulation of JAK-STAT pathways via overproduction of cytokines, such as interleukin-6, is involved in the pathogenesis of RA. Filgotinib is a selective JAK1 inhibitor pending approval for use in RA. By inhibition of the JAK-STAT pathway, filgotinib is effective in suppressing disease activity and preventing the progression of joint destruction. Similarly, interleukin-6 inhibitors such as tocilizumab also inhibit the JAK-STAT pathways by inhibition of interleukin-6 signaling. We present the protocol for a study that will evaluate whether the effectiveness of filgotinib monotherapy is non-inferior to that of tocilizumab monotherapy in RA patients with an inadequate response to MTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is an interventional, multicenter, randomized, open-label, parallel-group, and non-inferiority clinical trial with a 52-week follow-up. Study participants will be 400 RA patients with at least moderate disease activity during treatment with MTX. Participants will be randomized in a 1:1 ratio to administer filgotinib monotherapy or subcutaneous tocilizumab monotherapy switched from MTX. We will evaluate disease activity by measuring clinical disease activity indices and by using musculoskeletal ultrasound (MSUS). The primary endpoint is the proportion of patients who achieve an American College of Rheumatology 50 response at week 12. Secondary endpoints are changes from baseline in the MSUS scores. We will also comprehensively analyze serum levels of multiple biomarkers, such as cytokines and chemokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The study results are expected to show the non-inferiority of the effectiveness of filgotinib monotherapy to that of tocilizumab monotherapy in RA patients with inadequate response to MTX. The strength of this study is its prospective evaluation of therapeutic efficacy using not only clinical disease activity indices, but also MSUS, which accurately and objectively evaluates disease activity at the joint level among patients drawn from multiple centers with a standardized evaluation by MSUS. We will evaluate the effectiveness of both drugs by integrating multilateral assessments\u2014clinical disease activity indices, MSUS findings, and serum biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Japan Registry of Clinical Trials (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\">https:\/\/jrct.niph.go.jp<\/jats:ext-link>\n                      ) jRCTs071200107. Registered on March 3, 2021. ClinicalTrials.gov NCT05090410. Registered on October 22, 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07176-5","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T09:02:59Z","timestamp":1677834179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Toshimasa","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurika","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"7176_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094\u2013108.","journal-title":"Lancet"},{"key":"7176_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"7176_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"7176_CR4","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019;58:i4-16.","journal-title":"Rheumatology (Oxford)"},{"key":"7176_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315\u201325.","journal-title":"JAMA"},{"key":"7176_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848\u201358.","journal-title":"Ann Rheum Dis"},{"key":"7176_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet"},{"key":"7176_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med"},{"key":"7176_CR9","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"7176_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","volume":"72","author":"AN Colebatch","year":"2013","unstructured":"Colebatch AN, Edwards CJ, \u00d8stergaard M, van der Heijde D, Balint PV, D\u2019Agostino MA, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804\u201314.","journal-title":"Ann Rheum Dis"},{"key":"7176_CR11","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1136\/annrheumdis-2016-209646","volume":"75","author":"MA D'Agostino","year":"2016","unstructured":"D\u2019Agostino MA, Terslev L, Wakefield R, \u00d8stergaard M, Balint P, Naredo E, et al. Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. Ann Rheum Dis. 2016;75:1902\u20138.","journal-title":"Ann Rheum Dis"},{"key":"7176_CR12","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/art.23682","volume":"58","author":"E Naredo","year":"2008","unstructured":"Naredo E, M\u00f6ller I, Cruz A, Carmona L, Garrido J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:2248\u201356.","journal-title":"Arthritis Rheum"},{"key":"7176_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/14397595.2016.1221874","volume":"27","author":"SY Kawashiri","year":"2017","unstructured":"Kawashiri SY, Nishino A, Shimizu T, Umeda M, Fukui S, Nakashima Y, et al. Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2017;27:252\u20136.","journal-title":"Mod Rheumatol"},{"key":"7176_CR14","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/rheumatology\/keu217","volume":"53","author":"H Nguyen","year":"2014","unstructured":"Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53:2110\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"7176_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/rheumatology\/ket405","volume":"53","author":"SY Kawashiri","year":"2014","unstructured":"Kawashiri SY, Suzuki T, Nakashima Y, Horai Y, Okada A, Iwamoto N, et al. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatology (Oxford). 2014;53:562\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"7176_CR16","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3899\/jrheum.160193","volume":"43","author":"J Han","year":"2016","unstructured":"Han J, Geng Y, Deng X, Zhang Z. Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission: a systematic review and metaanalysis. J Rheumatol. 2016;43:2010\u20138.","journal-title":"J Rheumatol"},{"key":"7176_CR17","first-page":"887","volume":"45","author":"P Zufferey","year":"2018","unstructured":"Zufferey P, Scherer A, Nissen MJ, Ciurea A, Tamborrini G, Brulhart L, et al. Can ultrasound be used to predict loss of remission in patients with RA in a real-life setting? A multicenter cohort study J Rheumatol. 2018;45:887\u201394.","journal-title":"A multicenter cohort study J Rheumatol"},{"key":"7176_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"7176_CR19","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"key":"7176_CR20","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"7176_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/ard.2007.078451","volume":"67","author":"ST Torp-Pedersen","year":"2008","unstructured":"Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in colour\/power Doppler ultrasound in rheumatology. Ann Rheum Dis. 2008;67:143\u20139.","journal-title":"Ann Rheum Dis"},{"key":"7176_CR22","doi-asserted-by":"publisher","first-page":"e000237","DOI":"10.1136\/rmdopen-2015-000237","volume":"2","author":"MA D'Agostino","year":"2016","unstructured":"D\u2019Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, et al. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open. 2016;2:e000237.","journal-title":"RMD Open"},{"key":"7176_CR23","doi-asserted-by":"publisher","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","volume":"3","author":"L Terslev","year":"2017","unstructured":"Terslev L, Naredo E, Aegerter P, Wakefield RJ, Backhaus M, Balint P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open. 2017;3:e000427.","journal-title":"RMD Open"},{"key":"7176_CR24","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000;27:261\u20133.","journal-title":"J Rheumatol"},{"key":"7176_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"7176_CR26","first-page":"1175","volume":"40","author":"RW Mee","year":"1984","unstructured":"Mee RW. Confidence bounds for the difference between two probabilities (letter). Biometrics. 1984;40:1175\u20136.","journal-title":"Biometrics"},{"key":"7176_CR27","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2020","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020."},{"key":"7176_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/00031305.2018.1543137","volume":"73","author":"V Amrhein","year":"2019","unstructured":"Amrhein V, Trafimow D, Greenland S. Inferential statistics as descriptive statistics: there is no replication crisis if we don\u2019t expect replication. Am Stat. 2019;73:262\u201370.","journal-title":"Am Stat"},{"key":"7176_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213\u201326.","journal-title":"Stat Med"},{"key":"7176_CR30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"7176_CR31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727\u201338.","journal-title":"Ann Rheum Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07176-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07176-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07176-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T09:06:43Z","timestamp":1677834403000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07176-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7176"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07176-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1994034\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the certified review board of Nagasaki University. The reference number is CRB20-026. Written informed consent will be provided by the patients before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Results obtained in this trial will be published in an international journal and may be presented at international scientific meetings. This information will be included in the patient consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AK received research funding from ONO Pharmaceutical Co., Sanofi K.K., Asahi Kasei Pharma Corporation, Taisho Toyama Pharmaceutical Co., Teijin Pharma Co., Chugai Pharmaceutical Co., MSD Co., Kyowa Hakko Kirin Co., Boehringer Ingelheim Japan, AbbVie GK, Astellas Pharma Inc., Eli Lilly Japan, Daiichi Sankyo Co., Takeda Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Bristol-Myers Squibb, Alexion GK, Eisai Co., Celltrion Healthcare Co., AYUMI Pharmaceutical Co., Neopharma Japan Co., Novartis Pharma K.K., and Gilead Sciences, Inc. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}